Flexible bronchoscopy in young infants with hCoV-NL63-associated necrotizing laryngotracheobronchitis: findings and interventional value Authors: Xiangzhi Xu, Feizhou Zhang, Lingfang Liang, Li Yang, Zihao Yang, Lei Wu, Feng Wang, Lanfang Tang Published: 2026 ABSTRACT AbstractBackgroundHuman coronavirus NL63 (hCoV-NL63) is a major pathogen associated with pediatric acute respiratory tract infections. Although most infections are mild, severe lower airway complications have been increasingly reported. The aim of this study was to investigate the clinical and flexible bronchoscopy (FB) findings, as well as the interventional value, in young infants with hCoV-NL63-associated necrotizing laryngotracheobronchitis (NLTB).MethodsA retrospective case series was conducted at a tertiary pediatric intensive care unit between August 2025 and September 2025. Clinical data, including demographics, symptoms, imaging, FB findings, etiological test results, treatment strategies, and clinical outcomes of 3 young infants with confirmed hCoV‑NL63‑related NLTB were systematically analyzed.ResultsAll patients presented with progressive hoarseness, dyspnea, stridor, and upper airway obstruction as primary manifestations. FB demonstrated characteristic subglottic mucosal necrosis, ulceration, and airway stenosis in all cases. Urgent FB‑guided endotracheal intubation was successfully performed to secure the airway. Bronchoalveolar lavage fluid (BALF) examination confirmed hCoV‑NL63 infection, with concurrent Streptococcus pneumoniae detected in all samples. After comprehensive treatment including systemic glucocorticoids, broad‑spectrum antibiotics, airway management, and supportive care, all young infants showed significant clinical improvement, survived without serious complications, and were discharged successfully.ConclusionhCoV-NL63 may be associated with severe NLTB in young infants. FB may play a valuable and important role in early diagnosis, airway evaluation, and guided intubation. Multimodal therapy achieves favorable short‑term outcomes. Clinicians should strengthen awareness of this rare but severe entity to avoid delayed diagnosis and inappropriate intervention. This study is hypothesis-generating only, and larger studies are needed to confirm these results.Clinical trial numberNot applicable.Keywords: Bronchoscopy, Human Coronavirus NL63, Streptococcus pneumoniae, Laryngotracheobronchitis, Glucocorticoids Background Human coronaviruses (hCoVs) constitute a prominent etiological cause of acute respiratory tract infections in pediatric populations worldwide, with clinical manifestations ranging from self-limiting upper respiratory symptoms to severe lower respiratory tract complications, including bronchiolitis and pneumonia [1]. Among the six known pathogenic hCoVs, hCoV-NL63, first isolated in 2004 from a Dutch infant presenting with bronchiolitis, has emerged as a clinically significant pathogen in neonates and young infants, displaying distinct seasonal circulation peaks in temperate regions [2]. While most hCoV-NL63 infections follow a mild, self-resolving clinical course, accumulating evidence indicates that it can precipitate severe, airway-predominant disease in vulnerable cohorts, particularly immunocompromised young infants or those with underlying respiratory disorders [3]. Necrotizing laryngotracheobronchitis (NLTB) is a severe, life-threatening pediatric airway disorder characterized by progressive ulceration and necrosis of the laryngotracheobronchial mucosa, which frequently progresses to life-threatening airway obstruction, secondary bacterial superinfection, or acute respiratory distress syndrome [4, 5]. Traditionally associated with influenza A/B, parainfluenza virus or Mycoplasma pneumoniae [6–8], NLTB caused by hCoV-NL63 remains exceptionally rare in clinical literature. This paucity of clinical data has resulted in incomplete delineation of its phenotypic spectrum, diagnostic hallmarks, and optimal management strategies, gaps that can lead to delayed etiologic diagnosis or inadequate therapeutic approaches. Given the clinical significance of severe hCoV-NL63-associated respiratory disease and the inherent diagnostic challenges of NLTB, case series delineating such clinical manifestations are critical to refining clinical practice. Accordingly, this retrospective study evaluated the demographic, clinical, flexible bronchoscopy (FB), and therapeutic management data of 3 young infants with confirmed hCoV-NL63-associated NLTB admitted to the pediatric intensive care unit of our institution. The primary aim was to characterize the key clinical and FB features of this rare entity, and to offer evidence-based perspectives to support timely diagnosis and targeted therapeutic management. Methods Patient information collection Written informed consent was obtained from the parents or legal guardians of all patients prior to any intervention, covering both initial procedures and planned follow‑up examinations. Between August 2025 and September 2025, we identified 3 cases of hCoV-NL63-associated necrotizing laryngotracheobronchitis (NLTB) using the hospital medical record system. The search was conducted using keywords ‘Human coronavirus NL63’ and ‘Necrotizing Laryngotracheobronchitis’. Detailed information regarding their demographics, clinical manifestations, diagnosis, and treatment were recorded. High-resolution CT of the neck and chest High-resolution computed tomography (HRCT) images of the neck and chest were acquired for three pediatric patients using the same scanner model, GE Optima 660 MSCT. The scanning range extended from the base of the skull to the inferior surface of the lungs, ensuring comprehensive evaluation of the laryngotracheal tract and thoracic structures. Scanning parameters were set as follows: tube voltage of 100 kVp, automatic tube current modulation with a noise index of 8–10, and slice thickness of 5 mm. For patients under 5 years of age, sedation was achieved prior to scanning via oral or enema administration of 10% chloral hydrate at a dosage of 0.5 mL/kg, with a maximum total volume not exceeding 10 mL, to ensure motion-free image acquisition. Flexible bronchoscopy (FB) guided intubation, bronchoalveolar lavage (BAL), and serial follow-up At our institution, all pediatric flexible bronchoscopy (FB) procedures, including bronchoalveolar lavage (BAL), FB-guided endotracheal intubation (ETI), and serial follow-up FB examinations, were performed meticulously in strict compliance with the latest Chinese Guidelines for Pediatric FB. Preoperatively, a comprehensive assessment was conducted. This included essential laboratory tests (complete blood count, coagulation function assays) to evaluate hematological and hemostatic status. For patients with severe respiratory distress suggestive of airway obstruction, additional airway evaluation (e.g., bedside laryngoscopy) was performed to determine the suitability of FB-guided ETI. We also verified that all routine immunizations were up-to-date to mitigate perioperative infection risks. A critical component of our protocol involved detailed communication with parents or legal guardians: we explained the objectives of FB, BAL, and (when indicated) FB-guided ETI or planned follow-up FBs, and thoroughly discussed potential risks (e.g., anesthesia-related adverse events, airway trauma during intubation, post-lavage bleeding). Signed informed consent, covering both initial procedures and scheduled follow-ups, was obtained prior to any intervention to ensure informed decision-making. 3 young infants presenting with severe respiratory distress secondary to suspected NLTB, who demonstrated laryngotracheobronchial mucosal lesions and airway narrowing on neck-chest HRCT, met the indications for FB. These procedures were performed by experienced pediatric endoscopists per standardized protocols. Initial FB was conducted to assess airway morphology. BAL was performed in all cases to collect fluid for etiological testing (e.g., hCoV-NL63 nucleic acid detection), and FB-guided ETI was urgently performed in 3 young infants with severe airway obstruction and impending respiratory failure to secure the airway during the same session. All young infants received standardized procedural sedation and anesthesia before FB. Intravenous midazolam combined with fentanyl was administered for sedation and analgesia, and topical lidocaine was used for airway mucosal surface anesthesia. Continuous monitoring of heart rate, respiratory rate, blood pressure, and pulse oxygen saturation was performed throughout the procedure. No severe sedation-related or bronchoscopy-associated complications occurred in any of the three patients. Perioperative monitoring protocols were strictly enforced. Intraoperatively, vital signs (heart rate, blood pressure) and end-tidal carbon dioxide were continuously monitored. Postoperatively, we maintained close surveillance of oxygen saturation, electrocardiography, and clinical symptoms (dyspnea, hemoptysis, fever) to promptly identify complications, with immediate documentation and intervention for any abnormalities. Furthermore, serial follow-up FBs were scheduled at intervals individualized based on clinical response and initial FB findings (typically 3–7 days post-procedure) to assess healing of mucosal necrosis, evaluate airway patency, monitor endotracheal tube position (in intubated patients), and guide extubation timing and subsequent management. Case presentations The clinical baseline data of 3 young infants with hCoV-NL63-Associated necrotizing laryngotracheobronchitis (NLTB) are summarized in Table 1, imaging findings in Fig. 1 and FB findings in Fig. 2. The detailed case information is presented as follows. Table 1Clinical information of three infants with hCoV-NL63-associated necrotizing laryngotracheobronchitisCaseWBC(4–12* 109/mL)CRP(0–8 mg/L)SAA(1-10 mg/L)ESR(0–20 mm/h)PCT(< 0.05ng/ml)ALT(< 50U/L)AST(22-59U/L)D-dimer(< 0.55 mg/L)12-Plex Multiple Pathogen Nucleic Acid Test for Respiratory Tract (Throat Swab)NGS (BALF)110.2632.15184.7228.470.1412351.07 Coronavirus hCoV-NL63 + Streptococcus pneumoniae224.0112.5562.8913.60.130430.17 Coronavirus hCoV-NL63 + Streptococcus pneumoniae38.5310.85236.1322.020.0916360.72 Coronavirus hCoV-NL63 + Streptococcus pneumoniaeNote: WBC: White Blood Cell. Hs-CRP: High-Sensitivity C-Reactive Protein. ESR: Erythrocyte Sedimentation Rate. PCT: Procalcitonin. ALT: Alanine Aminotransferase. AST: Aspartate Aminotransferase. SAA: Serum Amyloid A. NGS: BALF: Next-Generation Sequencing. BALF: Bronchoalveolar Lavage Fluid Clinical information of three infants with hCoV-NL63-associated necrotizing laryngotracheobronchitis Note: WBC: White Blood Cell. Hs-CRP: High-Sensitivity C-Reactive Protein. ESR: Erythrocyte Sedimentation Rate. PCT: Procalcitonin. ALT: Alanine Aminotransferase. AST: Aspartate Aminotransferase. SAA: Serum Amyloid A. NGS: BALF: Next-Generation Sequencing. BALF: Bronchoalveolar Lavage Fluid High-resolution CT of the neck and chest signs of young infants with hCoV-NL63-associated necrotizing laryngotracheobronchitis Findings under flexible bronchoscopy and follow-up of young infants with hCoV-NL63-associated necrotizing laryngotracheobronchitis Case 1 A young female infant (under 2 years of age) was admitted for 2-day fever, cough, and 1-day hoarseness. She had a peak temperature of 39.3℃, along with paroxysmal cough and expectoration difficulty. Oral azithromycin for 2 days showed no significant improvement. She subsequently developed hoarseness complicated by wheezing, and laryngeal stridor was detected on auscultation, leading to her admission to the Department of Infectious Diseases of our hospital. On admission, her temperature was 37.8℃, blood pressure 108/73 mm Hg, heart rate 142 beats/min, respiratory rate 38 breaths/min, and SpO₂ 98% with face mask oxygen. She was conscious with a fair mental status, and pharyngeal erythema was noted. Tachypnea was present, accompanied by bilateral coarse breath sounds, positive triple concave sign, and audible inspiratory stridor. No peripheral edema or rash was observed. Cardiovascular and abdominal examinations were unremarkable. Admission laboratory and auxiliary examinations were conducted. complete blood count (CBC), high-sensitivity C-reactive protein (hs-CRP), and serum amyloid A (SAA) showed a normal white blood cell (WBC) count but markedly elevated hs-CRP and SAA. Additional abnormalities included elevated erythrocyte sedimentation rate (ESR), procalcitonin (PCT), and plasma D-dimer. Myocardial injury markers and five biochemical panels were unremarkable (Table 1). 12-plex respiratory pathogen nucleic acid testing was positive for coronavirus. Neck and chest CT revealed laryngeal airway stenosis (Fig. 1), and fiberoptic laryngoscopy showed vocal fold mucosal thickening. She was urgently transferred to the pediatric intensive care unit. Bedside FB confirmed necrotizing laryngotracheobronchitis (NLTB) (Fig. 2), and bronchoalveolar lavage fluid (BALF) next-generation sequencing (NGS) detected hCoV-NL63 (69548 copies) and Streptococcus pneumoniae (25094 copies) (Table 1). Endotracheal intubation (ETI) supplies were promptly prepared, followed by FB-guided intubation. Treatments included intravenous methylprednisolone sodium succinate (anti-inflammatory), nebulized epinephrine and budesonide suspension, and anti-infective therapy with ceftriaxone sodium plus linezolid to cover potential drug-resistant Gram-positive pathogens. Follow-up FB showed symptomatic improvement (Fig. 2), leading to endotracheal extubation and subsequent switch to nasal cannula oxygen. After achieving stable respiration, nasal cannula oxygen was discontinued, and she was transferred to the Department of Respiratory Medicine. Case 2 A young male infant was admitted for 2-day fever and 1-day progressive hoarseness with cough. His peak temperature was 39.8℃. He received topical Kaihoujian spray, a Chinese patent medicine containing menthol, honeysuckle, forsythia, and baicalin for throat discomfort, which failed to relieve symptoms, leading to his admission to the Department of Infectious Diseases of our hospital. On physical examination, his temperature was 38.8 °C (afebrile description corrected), blood pressure 84/48 mmHg, heart rate 158 beats/min, respiratory rate 48 breaths/min, and SpO₂ 99% with face mask oxygen. He was alert with fair mental status and pharyngeal erythema. Tachypnea was present, with positive triple concave sign, bilateral coarse breath sounds, and audible laryngeal stridor. No peripheral edema or rash was observed. Cardiovascular and abdominal examinations were unremarkable. Admission laboratory and imaging studies were performed. CBC, hs-CRP, and SAA showed marked elevations in WBC, hs-CRP, and SAA. Additional abnormalities included elevated ESR, PCT, and plasma D-dimer. Myocardial injury markers and five biochemical panels were unremarkable (Table 1). 12-plex respiratory pathogen nucleic acid testing was positive for coronavirus. Neck and chest CT revealed laryngeal airway stenosis (Fig. 1), and fiberoptic laryngoscopy showed vocal fold mucosal edema. He was urgently transferred to the PICU. Bedside FB confirmed NLTB (Fig. 2), and BALF NGS detected hCoV-NL63 (503522 copies) and Streptococcus pneumoniae (162326 copies). ETI supplies were promptly prepared, followed by FB-guided intubation. Treatments included intravenous methylprednisolone sodium succinate (anti-inflammatory), nebulized epinephrine and budesonide suspension, and anti-infective therapy with ceftriaxone sodium plus linezolid to cover potential drug-resistant Gram-positive pathogens. Cefoperazone‑sulbactam was chosen due to more severe clinical manifestations and higher inflammatory markers in this patient, as well as for better coverage of resistant bacterial strains in accordance with local antimicrobial resistance data. Follow-up FB showed symptomatic improvement (Fig. 2), leading to endotracheal extubation and subsequent switch to face mask or nasal cannula oxygen. After his respiration stabilized, oxygen therapy was discontinued, and he was transferred back to the Department of Infectious Diseases. Case 3 A young male infant was admitted for 2-day fever, 1-day cough, and 6-hour dyspnea. His peak temperature was 39.1℃, with barking cough, hoarseness, progressive dyspnea, tachypnea, and laryngeal stridor. At a local hospital, he received face mask oxygen, two nebulizations of epinephrine and budesonide suspension, two intravenous doses of methylprednisolone sodium succinate, and one intravenous dose of ceftriaxone. After slight symptomatic relief, he was transferred to our hospital’s pediatric intensive care unit via 120 emergency service. On physical examination, his temperature was 36.5 °C, blood pressure 108/64 mmHg, heart rate 159 beats/min, respiratory rate 33 breaths/min, and SpO₂ 100% under supplemental face‑mask oxygen therapy. He was alert with stable mental status. Mild tachypnea was present, with bilateral coarse breath sounds and positive triple concave sign. Cardiac, abdominal, and neurological examinations were unremarkable. Admission laboratory and imaging studies were performed. CBC and hs-CRP showed a normal WBC count but elevated hs-CRP. Additional abnormalities included elevated ESR, PCT, and plasma D-dimer. Myocardial injury markers and five biochemical panels were unremarkable. 12-plex respiratory pathogen nucleic acid testing was positive for coronavirus. Neck and chest CT revealed mild focal narrowing of the laryngeal airway. Bedside FB confirmed NLTB. BALF NGS detected hCoV-NL63 (134100 copies) and Streptococcus pneumoniae (279 copies). ETI supplies were promptly prepared, followed by flexible bronchoscope-guided intubation. Treatments included intravenous methylprednisolone sodium succinate (anti-inflammatory), nebulized epinephrine and budesonide suspension, and anti-infective therapy with ceftriaxone sodium plus linezolid to cover potential drug-resistant Gram-positive pathogens. Follow-up bronchoscopy showed symptomatic improvement (Fig. 2), leading to endotracheal extubation with subsequent switch to face mask or nasal cannula oxygen. After achieving stable respiration, oxygen therapy was discontinued, and he was discharged in improved condition. Discussion This single-center retrospective study delineates the clinical phenotypes, flexible bronchoscopy (FB) findings, and therapeutic outcomes of 3 young infants with confirmed human coronavirus NL63 (hCoV-NL63)-associated necrotizing laryngotracheobronchitis (NLTB). Our key findings, highlighting subglottic mucosal necrosis as a pathognomonic FB feature, the practical value of FB-guided endotracheal intubation (FB-guided ETI) for severe airway obstruction, and individualized airway management strategy, provide critical insights into this underreported, life-threatening pediatric airway disorder. By contextualizing these observations within the existing literature, we seek to optimize clinical decision-making and emphasize the need for enhanced recognition of hCoV-NL63 as a pathogenic driver of severe pediatric respiratory disease. Beyond its classical characterization as a causative agent of mild upper respiratory tract infections and non-severe bronchiolitis in children [9], hCoV-NL63 has long been underestimated as an etiologic driver of severe necrotizing airway disease. Our clinical observations further complement this perspective by confirming that hCoV-NL63 can trigger extensive laryngotracheobronchial mucosal injury and necrotic lesions. Notably, the following pathogenic explanations remain speculative mechanistic hypotheses, rather than definitive conclusions validated by our limited small case series. It is hypothesized that viral tropism and host immune dysregulation may jointly contribute to disease progression. hCoV-NL63 may potentially utilize ACE2 as an entry receptor on airway epithelial cells, causing direct epithelial damage and apoptosis; meanwhile, immature innate immunity and exaggerated inflammatory response in young infants may further aggravate mucosal edema and necrotic changes [10, 11]. Alternative viral entry pathways and immune regulatory mechanisms cannot be excluded, and larger clinical and basic studies are still required to verify these potential mechanisms [12, 13]. Notably, the detection of hCoV-NL63 in bronchoalveolar lavage fluid (BALF) via real-time reverse transcription-polymerase chain reaction (RT-PCR) confirms active viral replication in the lower respiratory tract, precluding mere upper airway colonization. This highlights the imperative of implementing comprehensive viral testing panels that include hCoV-NL63 for young infants presenting with progressive stridor and suspected NLTB, particularly in scenarios where traditional pathogens (e.g., influenza A/B virus, parainfluenza) are not identified. S. pneumoniae was detected in all cases, but with a low copy number in Case 3, suggesting it may serve as a copathogen or colonizer rather than a dominant severe co‑infection in this patient. Our data suggest that FB may play a valuable and important role in the multimodal management of hCoV-NL63-associated NLTB, encompassing diagnostic, interventional, and monitoring capabilities. Neck-chest HRCT in our cases showed nonspecific findings (e.g., tracheal wall thickening, luminal stenosis), whereas only FB allowed direct visualization of pathognomonic features: circumferential subglottic mucosal ulceration, fibrinopurulent exudate, and focal necrosis, findings that distinguish NLTB from mimickers such as viral croup (edematous, non-necrotic mucosa) or laryngomalacia (cartilaginous collapse). Additionally, FB facilitated targeted BALF sampling, which was pivotal for etiological confirmation. This is clinically relevant as routine nasopharyngeal swabs may fail to detect lower respiratory tract pathogens [14, 15]. All 3 young infants required urgent airway stabilization due to impending respiratory failure. FB-guided endotracheal intubation (ETI) conferred unique advantages over laryngoscope-guided intubation: real-time visualization of the narrowed, necrotic airway mitigated iatrogenic trauma, a significant risk associated with blind intubation, while direct visualization of the carina facilitated optimal tube positioning. This is particularly salient in NLTB, where fragile necrotic mucosa is susceptible to hemorrhage or further sloughing upon mechanical manipulation. Notably, a recent systematic review and meta-analysis comparing intubation techniques in patients with cervical spine immobilization demonstrated that while FB-guided intubation shares comparable safety profiles with video laryngoscopy in terms of overall complication rates (e.g., tissue damage, sore throat), FB-guided ETI in our NLTB cohort achieved complete avoidance of intubation-associated adverse events, underscoring its superior safety in the context of fragile necrotic airway mucosa, where minimizing mechanical trauma is paramount [16]. Serial FB, conducted every 3–7 days, resolved a key clinical conundrum: identifying the optimal timing for extubation when mucosal healing is adequate to sustain spontaneous respiration. Objective parameters (e.g., FiO₂ requirement, respiratory rate) were insufficient to detect residual airway narrowing in one infant. However, FB revealed persistent subglottic edema, prompting a 48-hour extubation delay and precluding reintubation. This is consistent with clinical guidelines that endorse FB-guided ETI in pediatric patients with structural airway disorders. Furthermore, follow-up FB enabled targeted debridement of residual necrotic debris in one case, facilitating rapid symptom resolution, an adjunctive therapeutic modality that is unattainable with medical therapy alone. Our therapeutic regimen, including systemic glucocorticoids, broad-spectrum antibiotics, and supportive care, was mainly extrapolated from clinical experience in viral croup and necrotizing tracheitis, given the lack of targeted therapeutic evidence for hCoV-NL63-associated NLTB. Methylprednisolone (2 mg/kg/day) was administered to attenuate the proinflammatory cascade underlying mucosal necrosis. Although evidence regarding glucocorticoid use in hCoV-NL63 infections remains scarce, their proven efficacy in reducing airway inflammation in viral croup and adenoviral tracheitis rationalizes this therapeutic strategy [17]. We observed rapid resolution of stridor within 48–72 h. Ceftriaxone was empirically initiated to target secondary bacterial superinfection, a well-documented complication of necrotic airway disorders. Despite negative BALF cultures in all cases, preemptive antibiotic administration likely precluded bacterial overgrowth in the compromised mucosal microenvironment. Linezolid was used to provide coverage for possible drug-resistant Gram-positive bacteria, which is a common concern in severe necrotizing airway infections with high inflammation. Low-tidal-volume mechanical ventilation (6–8 mL/kg) was employed to minimize barotrauma, a pivotal consideration in the context of fragile airway integrity. Since this is a case series without a control group, clinical improvement may be related to the natural course of the disease, and no causal conclusion about treatment efficacy can be drawn. This study is hypothesis-generating only. The findings should be considered preliminary and exploratory, and further research is needed to validate the role of FB and treatment strategies in hCoV-NL63-associated NLTB. Limitations This study has inherent limitations: the retrospective analysis of 3 cases limits generalizability, selection bias may have influenced patient outcomes, chronic sequelae (e.g., tracheal stenosis, bronchiectasis) were not evaluated, unavailability of whole-genome sequencing for hCoV-NL63 isolates precludes analysis of strain-specific virulence factors, and the absence of a control group hinders definitive attribution of outcomes to the therapeutic regimen. Notably, we performed nucleic acid sequencing of hCoV-NL63 in BALF using an in-house developed kit, revealing minimal sequence variation compared with previously reported strains. Our subsequent research will focus on exploring the interactive pathogenic mechanisms of hCoV-NL63 and Streptococcus pneumoniae in respiratory epithelial cells. Conclusion In conclusion, our small case series suggests that hCoV-NL63 may be associated with severe NLTB in young infants. FB may provide valuable diagnostic and interventional support in clinical management, and multimodal treatment may contribute to favorable short-term outcomes. Greater clinical awareness and further research are warranted to optimize the diagnosis and management of this rare condition. Acknowledgements We thank the patients and their parents for permitting us to use the data. Abbreviations Flexible Bronchoscopy Human coronavirus NL63 Necrotizing Laryngotracheobronchitis High-resolution computed tomography Endotracheal intubation Pronchoalveolar lavage Bronchoalveolar lavage fluid Complete blood count High-sensitivity C-reactive protein Serum amyloid A White blood cell Erythrocyte sedimentation rate Procalcitonin Next-generation sequencing Author contributions XXZ and ZFZ completed the first draft, LLF, YL, YZH and WL have participated to the data collection and improved the later revision of the article, WF and LFT revised the manuscript to ensure the authenticity and practicability. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. Funding This work was supported by the Innovation Team for the Diagnosis and Treatment of Childhood Asthma and the ‘Pioneer’ and ‘Leading Goose’ R&D Program of Zhejiang (No. 2026C02A1117). The funding did not engage in any aspect of the study including design, collection of data, writing of the report, or decision to submit for publication. Data availability All data generated or analyzed during this study are included in this published article. Declarations Ethics approval and consent to participate In accordance with the Declaration of Helsinki this study has obtained ethics approval and consent to participate. It was approved by the Ethics Committee of the Children’s Hospital Affiliated to Zhejiang University School of Medicine. Written informed consent was obtained from the parents or legal guardians of all participating children prior to their enrollment. Consent for publication The parents or legal guardians of all participants have provided written informed consent. This consent covers the publication of the participants’ personal clinical details and any identifying images included in this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xiangzhi Xu and Feizhou Zhang contributed equally to this work. Contributor Information Feng Wang, Email: fwang@cdc.zj.cn. Lanfang Tang, Email: 6195007@zju.edu.cn. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this published article.